Back to Newsroom

Puma Biotechnology Reports Positive Top Line Data from I-SPY 2 TRIAL Neratinib Graduates from I-SPY 2 TRIAL

LOS ANGELES, Calif., Dec. 4, 2013 – Puma Biotechnology, Inc. (NYSE: PBYI), a development stage biopharmaceutical compa ny, today announced top line results from the Phase II clinical trial of Puma’s investigational drug PB272 (neratinib) for the neoadjuvant treatment of breast cancer (I-SPY 2 TRIAL).